01—Abstract
Summary
Summary of the 8-K/A filed September 22, 2011. Cited figures are marked; the original filing is the authoritative source.
This Form 8-K/A filing by Techs Loanstar, Inc. (now effectively Quture, Inc.) announces an amendment to a previous filing, primarily to disclose the acquisition of Quture, Inc. The core event is a share exchange transaction completed on August 9, 2011, where Techs Loanstar acquired all outstanding capital stock of Quture in exchange for approximately 1.938 billion shares of Techs Loanstar's common stock.
This transaction resulted in Quture shareholders owning about 85%a of the combined entity. The company's business plan has been adopted from Quture, which focuses on developing standards for measuring clinical performance and outcomes in healthcare. Following the acquisition, the company's board of directors and officers were reconstituted.
The company's authorized shares were significantly increased to accommodate the share exchange. The filing also provides extensive detail on Quture's business, including its products (QualOptima and QSurg), target markets, competitive landscape, and the regulatory environment in healthcare. Investors should note the significant ownership concentration post-transaction and the numerous risk factors associated with a startup in this highly regulated and competitive industry.
02—Key points
Key Highlights
- Techs Loanstar, Inc. acquired Quture, Inc. via a share exchange on August 9, 2011.
- Quture shareholders now own approximately 85% of the combined entity.
- The company's business strategy is now centered on Quture's healthcare knowledge solutions, focusing on clinical performance and outcomes measurement.
- Key leadership changes occurred, with G. Landon Feazell appointed CEO and President.
- Authorized shares were increased from 900 million to 2.51 billion to facilitate the transaction.
- The company's primary products are QualOptima (performance measurement) and QSurg (surgery center EMR with analytics).
- Significant risk factors are highlighted, including limited operating history, need for financing, market acceptance of new products, and competitive pressures.
03—Questions
Frequently Asked Questions
What is the main purpose of this Form 8-K/A filing?
The primary purpose of this amended Form 8-K/A is to formally disclose the acquisition of Quture, Inc. by Techs Loanstar, Inc., which was a material definitive agreement and completion of an asset acquisition that occurred on August 9, 2011.
What business is the combined company now pursuing?
Following the share exchange, Techs Loanstar, Inc. has adopted Quture, Inc.'s business plan. Quture is an emerging healthcare knowledge solutions company focused on developing standards for measuring clinical performance and outcomes, leveraging clinical data and analytics.
Who controls the company after the acquisition?
Immediately after the share exchange, Quture shareholders, through Starslide Global Holdings, LLC, and G. Landon Feazell, collectively own approximately 85% of the issued and outstanding common stock. G. Landon Feazell, as CEO and President, holds significant influence.
What are the key products of the company moving forward?
The company will focus on two main products developed by Quture: QualOptima, a clinical performance measurement and analytics tool, and QSurg, an electronic medical record (EMR) system for surgery centers that includes embedded performance analytics.
04—Continue